Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 3:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 12,626 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Period A Clear all
Recruiting Not applicable Interventional

Resilience Through Interventions for Successful Early Outcomes

NCT06669624
View directory record Official record
Conditions
Parenting Intervention, Stress, Caregiver Child Relationship, Child Behavior Problem, Mental Health
Interventions
Attachment and Biobehavioral Catch-up (ABC), Waitlist with 4-month delay, then ABC
Behavioral · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chapel Hill, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 30, 2026, 3:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

PK Study of Testosterone Nasal Gel (TBS-2) in Healthy Premenopausal Women

NCT01364623
View directory record Official record
Conditions
Female Sexual Dysfunction
Interventions
Low dose testosterone nasal gel, single dose, Medium dose testosterone nasal gel, single dose, High dose testosterone nasal gel, single dose, Medium dose testosterone nasal gel, multiple dose
Drug
Lead sponsor
Acerus Pharmaceuticals Corporation
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Oct 30, 2026, 3:51 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)

NCT02073279
View directory record Official record
Conditions
Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)
Interventions
Satralizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 74 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
20
States / cities
Aurora, Colorado • Miami, Florida • Vero Beach, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 30, 2026, 3:51 PM EDT
Terminated Phase 1 Interventional

Safety Study of TXA127 to Elevate CD4+ T-Lymphocyte Counts in HIV-Infected Patients on Stable HAART Therapy

NCT00757250
View directory record Official record
Conditions
HIV Infections
Interventions
Angiotensin 1-7
Drug
Lead sponsor
US Biotest, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Los Angeles, California • San Diego, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Feb 29, 2012 · Synced Oct 30, 2026, 3:51 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating JUVÉDERM® VOLUMA® XC Injectable Gel for Correction of Temple Hollowing in Adult Participants ≥ 22 Years Old

NCT04414397
View directory record Official record
Conditions
Temple Hollowing
Interventions
JUVÉDERM® VOLUMA® XC, No-treatment control
Device · Other
Lead sponsor
Allergan
Industry
Eligibility
22 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
14
States / cities
Los Angeles, California • Newport Beach, California • Boca Raton, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 30, 2026, 3:51 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Cognizin Citicoline Dosing in a Healthy Adolescent Male Population

NCT01582113
View directory record Official record
Conditions
Neurocognitive Improvement
Interventions
Citicoline, Microcrystalline Cellulose
Drug · Other
Lead sponsor
Deborah Yurgelun-Todd
Other
Eligibility
13 Years to 18 Years · Male only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Oct 30, 2026, 3:51 PM EDT
Active, not recruiting Phase 2 Interventional

The Effect of Acupuncture on Cancer-Related Cognitive Difficulties

NCT04837820
View directory record Official record
Conditions
Breast Cancer
Interventions
Acupuncture, Sham Acupuncture, Wait-List Control (WLC), Questionnaires
Procedure · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 30, 2026, 3:51 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids

NCT01451424
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Proellex
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 47 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Miami Gardens, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2014 · Synced Oct 30, 2026, 3:51 PM EDT
Completed Phase 3 Interventional Results available

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

NCT01218659
View directory record Official record
Conditions
Fabry Disease
Interventions
migalastat hydrochloride, agalsidase
Drug · Biological
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
16 Years to 74 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Decatur, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Oct 30, 2026, 3:51 PM EDT
Completed Phase 2 Interventional Results available

Reduced Carbohydrate Versus Fat in Obese Subjects

NCT00846040
View directory record Official record
Conditions
Obesity
Interventions
Reduced fat diet, Reduced carbohydrate diet, Drug: f-18 fallypride, fMRI, PET
Other · Drug · Device
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 45 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 15, 2021 · Synced Oct 30, 2026, 3:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study of Bomedemstat and Carbamazepine in Healthy Adult Participants (MK-3543-020)

NCT06596668
View directory record Official record
Conditions
Healthy
Interventions
bomedemstat, carbamazepine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 30, 2026, 3:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29)

NCT06919991
View directory record Official record
Conditions
Healthy Participants
Interventions
Casdatifan, Itraconazole, Phenytoin
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 30, 2026, 3:51 PM EDT
Completed No phase listed Observational

Real-world Data Analysis of REN Treatment in Migraine Patients

NCT04992897
View directory record Official record
Conditions
Migraine
Interventions
Remote Electrical Neuromodulation (REN)
Device
Lead sponsor
Theranica
Industry
Eligibility
Not listed
Enrollment
12,151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 30, 2026, 3:51 PM EDT
Active, not recruiting Not applicable Interventional

Addressing Diabetes by Elevating Access to Nutrition

NCT05228860
View directory record Official record
Conditions
Diabetes, Obesity, Lifestyle, Healthy
Interventions
Vida Sana (a Group Lifestyle Intervention), Supplemental Healthy Food Deliveries
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Concord, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 30, 2026, 3:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Transcranial Direct Current Stimulation and Fear Extinction

NCT03907917
View directory record Official record
Conditions
Anxiety Disorders
Interventions
tDCS
Device
Lead sponsor
Thomas Adams
Other
Eligibility
18 Years to 55 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
2
States / cities
New Haven, Connecticut • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Oct 30, 2026, 3:51 PM EDT
Completed Phase 4 Interventional Results available

Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD

NCT00585910
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine and OROS Methylphenidate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2012 · Synced Oct 30, 2026, 3:51 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Substudy of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)

NCT02091882
View directory record Official record
Conditions
Device Latency
Interventions
Placebo, Combination product of Aripiprazole + IEM + Sensor + MIND1 Application
Drug · Combination Product
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 30, 2026, 3:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of 7.5 mg Pilocarpine Under Fed Conditions

NCT00618059
View directory record Official record
Conditions
Dry Mouth
Interventions
Pilocarpine
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 30, 2026, 3:51 PM EDT
Terminated Phase 3 Interventional Results available

A Study of PRN1008 in Patients With Pemphigus

NCT03762265
View directory record Official record
Conditions
Pemphigus
Interventions
Rilzabrutinib, Placebo
Drug
Lead sponsor
Principia Biopharma, a Sanofi Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
14
States / cities
Boca Raton, Florida • Coral Gables, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Oct 30, 2026, 3:51 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

A Self-administered PrEP Decisional Aid for Dissemination With HIV Self-test Kits (DASH)

NCT07614165
View directory record Official record
Conditions
Pre-Exposure Prophylaxis (PrEP), HIV Prevention
Interventions
PrEP Decisional Aid for dissemination with Self-administered HIV test kits (DASH)
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 39 Years
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 30, 2026, 3:51 PM EDT
Terminated Phase 3 Interventional Results available

An Efficacy and Safety Study of Ravulizumab in ALS Participants

NCT04248465
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS
Interventions
Placebo, Ravulizumab
Drug · Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
34
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Loma Linda, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Oct 30, 2026, 3:51 PM EDT
Completed Not applicable Interventional Results available

Tolerability, Acceptance, and Utility of Intermittent CGM Use in Youth With Prediabetes

NCT05505565
View directory record Official record
Conditions
PreDiabetes, Obesity, Insulin Resistance
Interventions
Abbott Freestyle Libre 2, Standard physical activity and nutritional counseling for prediabetes management
Device · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
11 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 30, 2026, 3:51 PM EDT
Completed Not applicable Interventional Results available

Clinical Biocompatibility Evaluation of Contact Lens Coatings

NCT03034928
View directory record Official record
Conditions
Refractive Errors, Ametropia
Interventions
Contact lens with investigational coating 1, Balafilcon A contact lens, OPTI-FREE® RepleniSH® MPDS, Contact lens with investigational coating 2
Device
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Johns Creek, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Oct 30, 2026, 3:51 PM EDT
Completed Phase 4 Interventional Results available

Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer

NCT00688909
View directory record Official record
Conditions
Breast Cancer
Interventions
letrozole
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older · Female only
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
48
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Grass Valley, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 30, 2026, 3:51 PM EDT